London · Delayed Price · Currency is GBP · Price in GBX ValiRx Statistics
Total Valuation
ValiRx has a market cap or net worth of GBP 1.23 million. The enterprise value is -20,249.
| Market Cap | 1.23M |
| Enterprise Value | -20,249 |
Important Dates
The last earnings date was Friday, July 3, 2026.
| Earnings Date | Jul 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ValiRx has 767.80 million shares outstanding. The number of shares has increased by 213.81% in one year.
| Current Share Class | 767.80M |
| Shares Outstanding | 767.80M |
| Shares Change (YoY) | +213.81% |
| Shares Change (QoQ) | +20.93% |
| Owned by Insiders (%) | 9.98% |
| Owned by Institutions (%) | 78.10% |
| Float | 690.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 39.16 |
| PB Ratio | 0.51 |
| P/TBV Ratio | 0.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.62, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.62 |
| Quick Ratio | 4.33 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | -547.62 |
Financial Efficiency
Return on equity (ROE) is -72.53% and return on invested capital (ROIC) is -36.01%.
| Return on Equity (ROE) | -72.53% |
| Return on Assets (ROA) | -33.05% |
| Return on Invested Capital (ROIC) | -36.01% |
| Return on Capital Employed (ROCE) | -76.05% |
| Weighted Average Cost of Capital (WACC) | 1.13% |
| Revenue Per Employee | 2,241 |
| Profits Per Employee | -159,440 |
| Employee Count | 14 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.55 |
Taxes
| Income Tax | -126,355 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.17% in the last 52 weeks. The beta is -0.61, so ValiRx's price volatility has been lower than the market average.
| Beta (5Y) | -0.61 |
| 52-Week Price Change | -74.17% |
| 50-Day Moving Average | 0.21 |
| 200-Day Moving Average | 0.32 |
| Relative Strength Index (RSI) | 27.08 |
| Average Volume (20 Days) | 7,033,454 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ValiRx had revenue of GBP 31,372 and -2.23 million in losses. Loss per share was -0.01.
| Revenue | 31,372 |
| Gross Profit | -6,250 |
| Operating Income | -1.82M |
| Pretax Income | -2.42M |
| Net Income | -2.23M |
| EBITDA | -1.59M |
| EBIT | -1.82M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 791,612 in cash and 1,395 in debt, with a net cash position of 790,217 or 0.00 per share.
| Cash & Cash Equivalents | 791,612 |
| Total Debt | 1,395 |
| Net Cash | 790,217 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 2.40M |
| Book Value Per Share | 0.01 |
| Working Capital | 850,862 |
Cash Flow
In the last 12 months, operating cash flow was -1.51 million and capital expenditures -13,580, giving a free cash flow of -1.52 million.
| Operating Cash Flow | -1.51M |
| Capital Expenditures | -13,580 |
| Depreciation & Amortization | 235,019 |
| Net Borrowing | -10,467 |
| Free Cash Flow | -1.52M |
| FCF Per Share | -0.00 |
Margins
| Gross Margin | -19.92% |
| Operating Margin | -5,809.21% |
| Pretax Margin | -7,699.03% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ValiRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -213.81% |
| Shareholder Yield | -213.81% |
| Earnings Yield | -181.70% |
| FCF Yield | -124.03% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 6, 2020. It was a reverse split with a ratio of 0.008.
| Last Split Date | Apr 6, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.008 |
Scores
ValiRx has an Altman Z-Score of -17.95 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -17.95 |
| Piotroski F-Score | 1 |